TEVA Pharmaceutical Industries
Ltd today announced the
appointment of a local md in John
Michailidis to head up its expansion
of commercial operations in
Australia.
Teva currently has an R&D facility
in Macquarie Park, Sydney and now
will take the next step to distribute
its main product, the multiple
sclerosis therapy Copaxone
(glatiramer acetate injection),
taking over from bioCSL.
The new arrangement will be
effective from March 2015 and Teva
has assured the 2,200 Australians
currently taking the medicine that
the transition will be seamless.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.